---
title: "Tempus AI Expands Collaboration With Gilead Sciences To Maximize Insights In Oncology Pipeline"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282204495.md"
description: "Tempus AI, Inc. has announced an expanded multi-year collaboration with Gilead Sciences, Inc. to enhance its oncology pipeline. The agreement allows Gilead access to Tempus' AI-driven Lens platform, which integrates extensive datasets and analytical services. This partnership aims to leverage Gilead's scientific expertise and Tempus' real-world data insights to generate critical insights for developing life-altering medicines. CEO Ryan Fukushima expressed enthusiasm for the collaboration, emphasizing its potential to navigate complex data for improved outcomes in oncology."
datetime: "2026-04-09T13:22:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282204495.md)
  - [en](https://longbridge.com/en/news/282204495.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282204495.md)
---

# Tempus AI Expands Collaboration With Gilead Sciences To Maximize Insights In Oncology Pipeline

Add  as your preferred news source on Google

 Add Now

Healthcare technology company Tempus AI, Inc. (TEM) Thursday announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (GILD) to build and advance its oncology pipeline.

As per the expanded agreement, Tempus AI will provide enterprise-wide access to its AI-driven Lens platform, unlocking access to broader datasets across multiple indications and integrating dedicated Tempus analytical services.

The combination of Gilead's scientific expertise with Tempus' real world data insights in oncology is expected to maximize generation of key insights.

Ryan Fukushima, CEO of Tempus Data & Apps said, "We are thrilled to expand this collaboration, offering the multimodal depth necessary to uncover critical biological insights. This approach helps navigate billions of data points to find the 'signal in the noise,' ultimately increasing the probability of success for life-altering medicines."

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [TEM.US](https://longbridge.com/en/quote/TEM.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)

## Related News & Research

- [<![CDATA[Gilead Enters $5 Billion Agreement to Acquire Tubulis ]]>](https://longbridge.com/en/news/281894501.md)
- [Gilead to Buy Cancer Biotech Tubulis in $5B Deal](https://longbridge.com/en/news/282092620.md)
- [Stock Yards Bank & Trust Co. Has $1.80 Million Position in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/282018622.md)
- [Morgan Stanley Reaffirms Their Buy Rating on Gilead Sciences (GILD)](https://longbridge.com/en/news/282345099.md)
- [Gilead Sciences Details Tubulis, Ouro, Arcellx Deals as Pipeline Catalyst, 2026 Updates Loom](https://longbridge.com/en/news/281940457.md)